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The regulation of the inhibitor of nuclear factor KB (IKB) by
interleukin 1 (IL1) was investigated in HeLa cells. Two forms of
IKB were resolved by ion-exchange chromatography. The major
form (75%) was identified as MAD3 by specific antisera. ILl
generated rapidly (6 min) an electrophoretically retarded form of
MAD3 that was stable in acid and was converted into the
unmodified form by phosphatase 2A. It thus corresponded to a
phosphorylation of the protein on serine or threonine. ILl also
caused the disappearance of MAD3 from the cells, which was
complete 15 min after stimulation and coincided with a 460%
reduction of cellular IKB activity. Newly-synthesized MAD3
accumulated to pre-stimulation levels between 60 and 90 min
after stimulation and this coincided with the down-regulation of
the phosphorylating activity. The serine proteinase inhibitors
3,4-dichloroisocoumarin (DCI) and tosylphenylalanyl chloro-
INTRODUCTION
A rapid cellular effect of the inflammatory cytokine interleukin 1
(ILl) is to activate the transcriptional regulator, nuclear factor
(NF) KB [1]. This response is mediated through the type I but not
the type II, receptor [2]. The mechanism of the activation, and
the post-receptor signalling events which cause it, are obscure.
NF-KB proteins are members of the rel family [3]. The best
characterized form is the activatable heterodimer of the DNA-
binding subunit p5O with p65. In resting cells, this heterodimer
resides in the cytoplasm, complexed with an inhibitory protein,
IKB [4]. Upon appropriate stimulation of the cells, for instance
by bacterial lipopolysaccharide (LPS), phorbol 12-myristate 13-
acetate (PMA) or cytokines, active heterodimer appears in the
nucleus where it is presumably bound to the KB DNA motif. To
date, the evidence points to the inhibitor, rather than the nuclear
factor itself, being modified during activation. For example,
activation is accompanied by down-regulation of cellular IKB
[4-9] and purified lKB proteins inhibit binding ofNF-KB to DNA
in vitro [4,10].
IKB was originally characterized as a cytoplasmic factor that
could be dissociated from NF-KB by sodium deoxycholate (DOC)
[4]. Two forms, IKBa and IKB/), were purified from human
methylketone (TPCK) prevented phosphorylation and disap-
pearance of MAD3. At the same concentrations (10-100 ,M),
they also increased basal phosphorylation of the small heat
shock protein (hsp27) and prevented the ILl- and phorbol 12-
myristate 13-acetate-induced increases of its phosphorylation.
The inhibitors were thus interfering with protein kinases when
blocking degradation ofMAD3. Recombinant MAD3 phospho-
rylated in vitro by protein kinase C was not electrophoretically
retarded, suggesting that MAD3 was phosphorylated by another
kinase in IL1-stimulated cells. Our results suggest that the ILl-
induced phosphorylation of MAD3 on serine or threonine leads
to its degradation. DCI and TPCK blocked phosphorylation
mechanisms and it could not be concluded that serine proteinases
were involved in the breakdown of MAD3.
placenta [10]. They differed in size, sensitivity to phosphatase
treatment and reactivity with NF-KB/rel proteins. The major
one, IKBa (37 kDa), inhibited only p65, whereas IKB,/ (43 kDa)
also prevented the binding of the c-rel gene product to the KB site
[5,11]. IKBa is presumed to be identical to a protein called
MAD3, whose cDNA was cloned from monocytes [12,13].
Several other IKBs have also been described. They include pp4O
[12], Bcl-3 [14], the p105 NF-KB precursor [15] and a 70 kDa
protein identical to its C-terminal portion, IKBy [16].
SincePMA is an activator ofprotein kinase C, phosphorylation
of IKB has been proposed as a major mechanism of NF-KB
activation [17]. Cell stimulants, such as LPS, ILl and tumour
necrosis factor (TNF), that activate NF-KB, cause phosphoryl-
ation and a concomitant loss of MAD3/IKBa [6-8,18-20], but
whether phosphorylation ofIKB is sufficient to release the nuclear
factor or whether degradation is also needed is unclear. Recent
reports have suggested that proteolysis is necessary for activation
since blocking degradation of MAD3 with serine proteinase
inhibitors prevents release of nuclear factor [6,19].
In order to understand how ILl impinges upon the NF-KB
system, we have characterized the forms of IKB in an ILl-
responsive cell. We have found that MAD3 was responsible for
most of the IKB activity of HeLa cells and that ILl induced its
Abbreviations used: DCI, 3,4-dichloroisocoumarin; DOC, sodium deoxycholate; DMEM, Dulbecco's modification of Eagle's medium; DTT,
dithiotheitol; E64, 1-trans-epoxysuccinyl-leucylamide(4-guanidino)butane; FCS, fetal calf serum; hsp27, small heat shock protein; IKB, inhibitor of NF-
KB; ILl, interleukin 1; LPS, bacterial lipopolysaccharide; MAP kinase, mitogen activated protein kinase; MAPKAP kinase, MAP kinase activated protein
kinase; NF-KB, nuclear factor KB; NP40, Nonidet P40; PMA, phorbol 12-myristatel3-acetate; PMSF, phenylmethanesulphonyl fluoride; PP,
phosphoprotein phosphatase; PTP, phosphotyrosine phosphatase; TPCK, tosylphenylalanyl chloromethylketone; TNF, tumour necrosis factor.
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phosphorylation on serine or threonine and its degradation.
Inhibitors of serine proteinases were used to try to cause
accumulation of the phosphorylated form, but they prevented
the ILl-induced breakdown of MAD3 by interfering with
intracellular signalling by ILI. Our evidence nevertheless sug-




HeLa cells and Dulbecco's modified Eagle's medium (DMEM)
were from Flow Laboratories (Rickmansworth, U.K.). Fetal calf
serum (FCS) was from GIBCO (Uxbridge, U.K.). Recombinant
human ILla was purified as described [21]. Recombinant human
phosphotyrosine phosphatase (PTP) 1B was given by Dr. D.
Barford (Department of Molecular Biophysics, University of
Oxford, U.K.). The catalytic subunit of phosphoprotein phos-
phatase 2A (PP2A) was purified from rabbit muscle as described
[22]. Its specific activity was 3300 units/mg, one unit being the
amount of enzyme releasing 1 nmol of phosphate per minute
from phosphorylase a. Okadaic acid was from Calbiochem-
Novabiochem (U.K.). PMA, phenylmethanesulphonyl fluoride
(PMSF), Hepes buffer, 3,4-dichloroisocoumarin (DCI), 1-trans-
epoxysuccinyl-leucylamide(4-guanidino)butane (E64), NaF,
Na3VO4, fi-glycerophosphate, tosylphenylalanyl chloromethyl-
ketone (TPCK), BSA, calf thymus double-stranded DNA-cellu-
lose, DOC, Nonidet P40 (NP40), TPCK-treated trypsin, soybean
trypsin inhibitor and protein A-coupled agarose were supplied
by Sigma. [y32P]ATP for labelling of oligonucleotides (7000 Ci/
mmol) was from ICN Biomedicals Ltd. (Bucks., U.K.) and
[y32P]ATP for phosphorylation of proteins in vitro (3200 Ci/
mmol) was from Amersham plc (Little Chalfont, U.K). 1251_
labelled donkey antibody against rabbit immunoglobulin
(750-3000 Ci/mmol) and [32P]orthophosphoric acid (9000 Ci/
mmol) were from Amersham plc. T4 polynucleotide kinase was
from Stratagene (Cambridge, U.K.) and poly(dI-dC) was from
Pharmacia (Milton Keynes, U.K.). A synthetic peptide with the
sequence of residues 6-20 of MAD3 (peptide 6-20, ERPQEW-
AMEGPRDGL) and antigen affinity-purified rabbit antibodies
to it (Ab 6-20) were from NBS Biological, Hatfield, U.K.
Baculovirus-expressed recombinant MAD3 was a gift from Dr
Martha Ladner (Chiron Corporation, Emeryville, CA, U.S.A.)
The rabbit antisera to it (ASlO) and to the synthetic peptide
(AS9) were made by standard methods. Rabbit antiserum to the
human small heat shock protein (hsp27) was made against
homogenous antigen purified from ME180 cells as described
elsewhere [23] by N. Freshney in this laboratory. Protein kinase
C (a, /3, y) purified from bovine brain [24] was a gift from Dr P.
Parker (ICRF Laboratories, London, U.K.).
Cell culture
HeLa cells were maintained in DMEM containing 10% (v/v)
heat-inactivated FCS at 37 °C in a humidified 95 % air- 5% CO2
atmosphere. Confluent cells grown in 10 cm2 wells or 175 cm2
flasks were used for experiments.
Preparation of nuclear extracts and cytosolic fractions
Cell extracts were prepared according to published methods
[1,25]. HeLa cells grown in flasks were detached, either by
treatment with trypsin/EDTA in PBS, or by placing the flasks on
ice and scraping the cells in ice-cold PBS: both methods gave
similar results (not shown). Detached cells were placed on ice and
buffer [buffer A: 10 mM Hepes, pH 7/1.5 mM MgCl2/10 mM
KCI/0.05 mM dithiothreitol (DTT)/0.3 mM DCI/0.1 mM
E64/l1 /g/ml pepstatin/0.1 mM phenanthroline/lO mM NaF/
25 mM ,-glycerophosphate/0. 1 mM Na3VO4]. They were then
lysed for 10 min on ice in buffer A containing 0.1 % NP-40.
Lysates were centrifuged for 10 min at 10000 g at 4 °C and the
supernatants were kept as cytosolic fractions.
The pelleted nuclei were resuspended in extraction buffer
[buffer C: 20 mM Hepes, pH 7.9/420 mM NaCl/ 1.5 mM MgCl2/
0.2 mM EDTA/25 % (v/v) glycerol/0.5 mM PMSF/0.5 mM
DTT] and incubated at 4 °C for 15 min. Nuclei were then
centrifuged for 10 min at 10000 g at 4 °C and the supernatants,
referred to as the nuclear extracts, were supplemented with a
5-fold volume of storage buffer [buffer D: 20 mM Hepes,
pH 7.9/50 mM KC1/0.2 mM EDTA/20% (v/v) glycerol/
0.5 mM PMSF/0.5 mM DTT] [1]. These extracts were snap
frozen and stored at -70 'C.
Electrophoretic mobility shift assay
NF-KB binding activity was detected with synthetic oligonucleo-
tide probes. The wild-type KB (5'-AGCTTGGGGACTTTC-
CGAG-3') or mutant KB (5'-AGCTTGCTCACTTTCCGAG-
3') oligonucleotides were radiolabelled with [y-32P]ATP by T4
polynucleotide kinase. They were then isolated by precipitation
with ammonium acetate/ethanol and purified by precipitation
with 800% ethanol.
DNA-binding reactions were performed in a total volume of
20,ul containing the binding buffer [10 mM Tris/HCl,
pH 7.5/100 mM NaCl/1 mM EDTA/4% (v/v) glycerol/5 mM
DTT/100 /sg/ml BSA], the sample, an aliquot of 32P-labelled
oligonucleotide (105 c.p.m.) and 3 ,tg of poly (dI-dC). After
incubation for 15 min at room temperature, samples were
electrophoresed in a 5% polyacrylamide gel in a 22.5 mM Tris-
borate buffer containing 0.5 mM EDTA [26]. After electro-
phoresis gels were dried and then autoradiographed by exposure
to medical X-ray film. For quantification, the DNA-protein
complex bands were located by autoradiography, excised and
radioactivity was measured by Cerenkov counting.
Measurement of IKB activity
Samples to be assayed for lKB activity (4-10 ,ug of protein) were
preincubated for 5 min with standard amounts (6 ,ug of protein)
of nuclear extract preparations from IL-1-stimulated HeLa cells
containing NF-KB. Control incubations of the nuclear extract
without samples were also carried out. DNA-binding reactions
and the electrophoretic mobility shift assay were then performed.
In the case of DOC-treated cytosolic samples, NP40 was added
to a final concentration of 1.2% before electrophoresis. Trials
using varying amounts of recombinant MAD3 or flow-through
fractions of cytosols showed that inhibition of NF-KB activity
was proportional to the amount of sample (results not shown).
Preparation of l1cB from HeLa cells
Crude IKB was prepared essentially as described previously [4].
Briefly, HeLa cytosolic proteins (6 mg) were adjusted to 0.6%
DOC in a final volume of 1 ml and applied to a 0.5 ml calf
thymus double-stranded DNA-cellulose column. The column
was first equilibrated with buffer G [10 mM Tris/HCl, pH 7.5/
50 mM NaCl/l mM EDTA/1 mM DTT/5% (v/v) glycerol/
0.2% DOC/0.2 % NP40/0.5 mM PMSF]. Material that failed
to bind to the column was collected and NP40 was added to a
final concentration of 1.20%. This was saved for assay of IKB
washed firstly in ice-cold PBS and then in ice-cold hypotonic activity. The DNA-cellulose was finally eluted with buffer G
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containing 0.5 M NaCl. The eluate was dialysed against buffer
G and then tested for NF-KB by the electromobility shift assay.
For further purification of IKB, the flow-through fraction from
a sample of 12 mg of cytosolic protein was dialysed against
buffer D [20 mM Hepes, pH 7.9/50 mM KCI/0.2 mM EDTA/
100% (v/v) glycerol/0.5 mM PMSF/0.5 mM DTT/0.25 %
NP40], and subjected to anion-exchange chromatography on a
HR 5/5 Mono Q column (Pharmacia) equilibrated with buffer
D. The column was eluted at a flow rate of 1 ml/min with a linear
salt gradient (0.05-1 M KCl) in an FPLC system (Pharmacia).
Metabolic labelling of cells
Cells grown in 10 cm2 wells were washed twice for 15 min in
phosphate-free DMEM (ICN) supplemented with 20 mM Hepes/
NaOH (pH 7.5) and 1 % heat-inactivated FCS that had been
dialysed against 150 mM NaCI (labelling medium). They were
then incubated for 6 h in 2 ml/well of labelling medium supple-
mented with 50uCi/ml [32P]orthophosphoric acid [27].
Preparation of lysates
Plates or flasks were put on ice and the cells were washed for
1 min in ice-cold PBS. Next, they were taken into chilled
immunoprecipitation buffer [40 mM Tris/HCl, pH 7.5/100 mM
NaCl/1 % (w/v) NP40/1 % (w/v) DOC/0.1 % (w/v) SDS/
50 mM /-glycerophosphate/50 mM NaF/200,#M sodium ortho-
vanadate/ 1 mM EDTA/1 mM EGTA/0.02% NaN3] freshly
supplemented with 1 mM PMSF, 1 mM orthophenanthroline,
10,M E64 and 1 #uM pepstatin A (500,ul/well or 5 ml/flask).
The resulting lysates were stirred thorougly (30 s on whirlmix,
maximum speed), left on ice for 20 min, cleared by centrifugation
(5 min, 11000 g) and kept at -20 'C.
Immunoprecipitation of MAD3 and hsp27
The immunoprecipitation procedure was carried out at 4 'C.
Lysates were precleared by incubation for 30 min with 40 4ul of a
1:1 (v/v) suspension of protein A-agarose in immuno-
precipitation buffer. The protein A-agarose was then left to
settle. Immunoprecipitations were carried out by incubating the
supernatants for 3 h with serum (0.5 %, v/v) or purified anti-
bodies (1 tg/ml). Protein A-agarose (10,ul of packed beads) was
then added and the incubation was continued for a further
30 min with occasional mixing. The beads were then washed five
times with immunoprecipitation buffer (1 ml per wash).
SDS/PAGE
Cell lysates were mixed directly with twice-concentrated SDS/
PAGE sample buffer. For Mono Q fractions, proteins were
precipitated by addition of carrier BSA (50 /tg/ml) and 0.4 vol.
of 20% trichloroacetic acid (10 min, 4 'C), the precipitates were
collected by centrifugation (10 min, 10000 g), washed with diethyl
ether, dried, and dissolved in SDS/PAGE sample buffer. Immu-
noprecipitates were taken into SDS/PAGE sample buffer. The
samples were heated (100 'C, 3 min) and electrophoresed on
gels containing 11.50% acrylamide and 0.31 % bis-acrylamide
for MAD3, or 12.5% acrylamide and 0.33 % bis-acrylamide for
hsp27 [28]. Gels were then either stained with Coomassie Brilliant
Blue and dried or Western blotted.
Western blotting
The gels were electrotransferred to nitrocellulose (250 mA, 6 h)
in a buffer containing 25 mM Tris base, 192 mM glycine and
20% methanol (v/v). The membrane was incubated for 1 h at
37 °C in blocking buffer [1OmM Tris/HCl, pH 7.4, 154 mM
NaCl, 1 % (w/v) BSA and 1 % (w/v) milk powder], then in
blocking buffer supplemented with antiserum (1: 500, v/v) or Ab
6-20 (0.67 /tg/ml) for 16 h at 4 'C. After ten washes in Tris-
buffered saline (1OmM Tris/HCl, pH 7.4/154mM NaCl), the
membrane was incubated at room temperature for 30 min in
blocking buffer followed by 4 h in blocking buffer supplemented
with 125I-labelled antibody to rabbit immunoglobulin (0.25-
0.5#0Ci/ml). The blots were finally washed ten times in Tris-
buffered saline, air dried and exposed to medical X-ray film.
They were quantified by counting bands excised from nitro-
cellulose in a Packard Auto Gamma 500 counter.
Activation of protein kinase C
Bovine protein kinase C (a, / and y) was incubated at 75 ,ug/ml
in 10 mM Tris, pH 8.0, buffer containing 10 mM 2-mercapto-
ethanol, 0.5 mg/ml BSA and 5 #g/ml trypsin for 2.5 min at
30 'C. The reaction was stopped by addition of soybean trypsin
inhibitor to a final concentration of 150 ,g/ml. The activity of
the enzyme was measured on histone HI substrate (1.25 mg/ml)
as described [24], except that CaCI2, PMA, phosphatidyl serine
and Triton X-100 were omitted; 1 unit transfers 1 nmol of
phosphate per min.
RESULTS
MAD3 Is the major form of lxcB in HeLa cells
Antisera to a recombinant MAD3 containing a tag of seven extra
amino acids at its C-terminus [13], ASIO, or to a synthetic
peptide corresponding to residues 6-20 of the protein, AS9, and
affinity-purified antibodies to the same peptide, Ab 6-20, were
used to check whether or not the protein was expressed in HeLa
cells. AS9 has been used in previous studies of MAD3 and its
specificity is well documented [18,20].
Several antigens were detected when cell lysates were subjected
to Western blot with either Ab 6-20 (Figure 1, lane 1), or with
ASIO (Figure 1, lane 5), but only one antigen, of about 38 kDa,
was detected equally well by the serum and the antibodies
Ab 6-20 blot











Figure 1 ldentmcation of MAD3-related antigens In lysates of HeLa cells
by Western blotting
Hela cells grown in flasks were lysed in immunoprecipitation buffer as described in the
Materials and Methods section. Immunoprecipitations were carried out on 1 ml aliquots of the
lysate with a non-immune rabbit serum (lane 2), antisera raised against the recombinant protein
(AS1 0, lane 3) or a synthetic peptide of MAD3 (AS9, lane 4) and affinity-purified antibodies to
the same peptide, Ab 6-20, that had been either preincubated for 2 h with excess control
peptide (lane 6) or not (lane 7). Samples of the lysate (100 jul, lanes 1 and 5), immunoprecipitates
(lanes 2-4, 6 and 7) and 2.5 ng of baculovirally-expressed recombinant MAD3 (lane 8) were
subjected to SDS/PAGE and Western blotting with either Ab 6-20, (lanes 1-4) or AS10 (lanes
5-8). Strips of autoradiographs containing proteins in the 50-25 kDa range are shown. The
molecular mass markers ovalbumin (45 kDa) and carbonic anhydrase (29 kDa) are indicated.
The positions of the 38 kDa antigen and of the recombinant MAD3 are indicated by arrows and
an arrowhead respectively.
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Figure 2 Mono Q anion-exchange chromatography of HeLa cell IKB
Cytoplasmic extracts of resting HeLa cells were treated with 0.6% DOC, chromatographed on DNA-cellulose and applied to a Mono Q column as described in the Marerials and Methods section.
The column was eluted with a gradient of 0.05-1 M KCI and 1 ml fractions were collected. (a) IKB activity assay: samples of Mono 0 fractions were incubated for 5 min with a standard amount
of nuclear extract containing NF-KB. The mixtures were subjected to electrophoretic mobility shift assay as described in the Materials and Methods section and the gels were then autoradiographed.
Strips of the autoradiographs containing the probe-NF-KB complexes are shown. Fraction numbers are indicated on top. (b) Fractions 14-18 were Western blotted with AS9 as described in the
Materials and Methods section. The positions of molecular mass markers (kDa) are shown on the left and the arrow indicates that of the 38 kDa antigen. Fraction numbers are indicated. (c) As
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Figure 3 Neutralizatlon of HeLa cell IKB activity by the antiserum to MAD3, AS10
Recombinant MAD3 (1 ng, lanes 2 and 3), DNA-cellulose flow-through fraction of cytosol (5 ,u1, lanes 4 and 5) or Mono 0 fractions 16 (lanes 7-10) and 27 (lanes 11-14) of the chrornatogram
shown in Figure 2 were incubated for 16 h at 4 °C with 5 jpl of either antiserum AS10 or pre-immune serum, as indicated. Controls without serum and IKB-containing samples were also carried
out (lanes 1 and 6). The mixtures were then assayed for IKB activity by incubation with a standard amount of NF-KB-containing nuclear extract followed by electrophoresis as in Figure 2a. The
probe-NF-KB complexes are indicated by arrows.
(arrow). The 38 kDa antigen was precipitated by AS10, AS9
and Ab 6-20 (lanes 3, 4 and 7), but not by pre-immune serum to
ASIO (lane 2) or by Ab 6-20 that had been pre-incubated with
excess peptide antigen (lane 6). Its molecular mass corresponded
to that reported for MAD3 [13] and Western blots of two-
dimensional electrophoresis gels showed that it had the same
isoelectric point as the recombinant protein (results not shown).
The difference in molecular mass between the 38 kDa antigen
and the recombinant MAD3 (Figure 1, lanes 7 and 8) was that
expected from the extra seven amino acids of the latter [13]. The
38 kDa protein was thus identified as MAD3. Quantifications of
Western blots in which recombinant protein was used as a
standard showed that about 10 ng of MAD3 was immuno-
precipitated under our conditions (results not shown).
In order to assess the contribution of MAD3 to the cellular
IKB activity, the distributions of activity and antigen in anion-
exchange chromatography fractions of NF-cB-depleted cytosols
were compared (Figure 2). Cytosols of unstimulated cells were
: : ::, .. ... .. .................. ... ...: > c . ... : :
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Table I Reduction of cytosolic IKB activity of HeLa cells by ILl or PMA
Cells were left resting or were stimulated with ILl (10 ng/ml, 15 min) or PMA (100 ng/ml, 1 h).
DNA-cellulose flow-through fractions of DOC-treated cytosols were then prepared and samples
were incubated with a standard amount of NF-KB as in Figure 2(a). Control incubations without
samples were also carried out. The mixtures were then subjected to electrophoretic mobility shift
assays. The probe-NF-KB complexes were located by autoradiography and their amounts were
quantified by Cerenkov counting. The experiments were done with probes of different specific
activities. IKB activity (column 5) was calculated as the percentage reduction in the amount of
probe-NF-KB complex formed in the presence of sample (column 4), relative to the amount
formed without sample (column 2). The reduction in IKB activity in fractions from stimulated
cells was then expressed as the percentage reduction relative to the activity in fractions from
resting cells (column 6).
NF-KB activity NF-KB activity Inhibition of NF-KB Reduction in IKB
without sample with sample by cytosolic activity by
Experiment (c.p.m.) Stimulant (c.p.m.) traction (%) stimulant (%)
1 2320 ILl 1759 24 47
None 1270 45
2 919 ILl 632 31 48
None 366 60
3 4630 ILl 3634 22 58
None 2201 52
4 1846 ILl 913 50 27
None 572 69
5 1549 PMA 882 43 30
None 592 62
6 4630 PMA 3694 20 68
None 1694 63
7 1846 PMA 880 52 32
None 439 76
treated with 0.6% DOC to dissociate lKB from cytosolic NF-KB
and applied to aDNA cellulose column to retain the transcription
factor. The NF-KB-depleted flow-through was then chromato-
graphed on Mono Q. Fractions were screened for lKB activity by
incubating them with a standard nuclear extract containing NF-
KB and subjecting the mixtures to electrophoretic mobility shift
assay. The resulting autoradiograph (Figure 2a) shows that two
regions of the chromatogram contained factors that interfered
with the formation of the probe-NF-KB complex. The first
component eluted at around 0.4 M KCI (Figure 2a, fractions
16-18), the second at 0.85 M KCI (Figure 2a, fraction 27 and 28).
Quantifications showed that they accounted for about 75 and
25% of the total IKB activity of the chromatogram respectively.
Western blotting with antisera AS9 and ASIO showed that
MAD3 co-eluted with the major IKB detected by the electro-
mobility shift assay (Figures 2b and 2c, fraction 16). No antigen
was detected by Western blotting with either antiserum in the
minor IKB peak, fractions 27 and 28 (results not shown).
Incubation of recombinant MAD3 with the antiserum to it,
AS10, prevented the protein from inhibiting formation of the
probe-NF-KB complex, whereas the corresponding pre-immune
serum had no effect (Figure 3, lanes 1-3). This indicated that
ASIO was specifically neutralizing MAD3, and we used this
property to check whether or not the 38 kDa antigen had IKB
activity (Figure 3). AS10, but not the pre-immune serum, strongly
inhibited the lKB activities of the flow-through fraction from the
DNA column (lane 5) and of Mono Q fractions 16 (lanes 8 and
10), thus increasing binding of NF-KB to the probe. By contrast,
the minor IKB peak (Mono Q fraction 27) was only partially
inhibited by ASIO (lanes 12 and 14) relative to controls with the
non-immune serum (lanes 11 and 13). MAD3 was thus re-
sponsible for the major form of IKB of the Mono Q chromato-
gram (fraction 16) and the later-eluting, minor form of IKB
(fraction 27) was also immunologically related to it. It was
concluded that most (75 %) of the lKB activity in the cell extracts
was due to MAD3.
Reduction of IKB activity In the cytosol of HeLa cells after
stimulation by ILl or PMA
The IKB activity of the flow-through fractions of unstimulated
and stimulated cells was measured in seven different experiments
(Table 1), four with ILl and three with PMA. Stimulation times
of 15 min for ILl and 60 min for PMA were chosen because in
time-course experiments they were found to coincide with
maximal activation ofNF-KB (results not shown). Table 1 shows
that ILl or PMA partially reduced the lKB activity of the extracts
in all experiments, the reduction ranging from 27 to 68% and
being on average 46% for ILl and 43 % for PMA. The two
stimulants thus caused quantitatively similar down-regulation of
IKB activity.
ILl-Induced phosphorylation and degradation ot MAD3
Stimulation of HeLa cells by ILl caused disappearance of
MAD3, which started 6 min after stimulation and was complete
between 15 and 45 min after stimulation (Figure 4a). The antigen
then gradually reappeared and returned to pre-stimulation
amounts between 60 and 90 min after stimulation. When the
antiserum to the protein AS IO was used instead of AS9, the same
loss of antigen was observed and no truncated form of the
protein was detected (results not shown). This indicated that
MAD3 was being degraded rather than undergoing a modifi-
cation preventing its recognition by antibodies to its N-terminus.
Interestingly, the onset of the degradation ofMAD3 coincided
with the generation of a form of the antigen with reduced
electrophoretic mobility (Figure 4a, 6 and 10 min). This modified
form was also detected when the antigen reappeared in cells
60 min after stimulation, but was no longer detectable when it
had returned to pre-stimulation levels (90 min). The reduction of
mobility indicated that ILI was causing a modification ofMAD3,
possibly a phosphorylation, over a time-course that matched
that of the degradation of the protein.
Attempts to detect the modified form of MAD3 by immuno-
precipitation from cells metabollically labelled with 2 mCi/well
of [32P]orthophosphoric acid were unsuccesful. No labelled
protein was specifically precipitated by AS9 or AS IO from resting
or stimulated cells (results not shown). However, the slower
migrating modified form of MAD3, detected by Western blot,
was converted into the unmodified form of the protein by the
phosphatase PP2A (Figure 4b, lane 2). This could be prevented
by okadaic acid (lane 3), showing that the reduction in mobility
corresponded to a phosphorylation. Incubations with the phos-
photyrosine phosphatase, PTP-lB (lane 4), or with 0.1 M HCI
(Figure 4c, lane 2) had no effect. PP2A is known generally as a
phosphoserine/phosphothreonine phosphatase, but also dephos-
phorylates the acid-labile phosphoamino acid, phosphohistidine
[29]. The stability of the phosphorylation of MAD3 in acid
indicated that it was on either a serine or a threonine residue.
Failure to detect it as a 32P-labelled protein was thus not
attributable to the possible degradation of an acid-labile phos-
phorylation during gel staining.
Isocoumarin and chloromethylketone protelnase Inhibitors prevent
cytokine and PMA slgnailng: effects on hsp27 phosphorylatlon
Certain inhibitors of serine proteinases have recently been
reported to inhibit the activation of NF-KB by TNF or PMA by
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Figure 4 ILl-induced phosphorylation and breakdown of MAD3
(a) Cells grown in wells were stimulated with 20 ng/ml ILl for the indicated times, then lysed. Immunoprecipitation and Western blotting were both carried out with Ab 6-20 as in Figure 1. Strips
of autoradiographs containing the antigen are shown. (b) HeLa cells grown in two flasks were stimulated for 6 min with 20 ng/ml ILl and lysed. MAD3 was immunoprecipitated with Ab 6-20
as before and the immunoprecipitate was then washed a further four times in phosphatase buffer [20 mM Tris/HCI, pH 7.5/0.1 mM EGTA/20% (v/v) glycerol] at 4 °C. It was finally resuspended
in phosphatase buffer supplemented with 0.1 % 2-mercaptoethanol and split into five aliquots. One was left on ice (lane 1), the others were incubated at 30 °C for 30 min with 40 units/ml PP2A
(lane 2), 40 units/ml PP2A and 50 ,uM okadaic acid (lane 3), 100 ,g/mI PTP-1 B (lane 4) or 100 ,ug/ml PTP-1 B and 2 mM sodium orthovanadate (lane 5) with occasional resuspension of the
protein A-agarose beads (every 5 min). Electrophoresis and Western blotting were then carried out as in (a). (c) An immunoprecipitate was prepared from one flask of stimulated cells as in (a),
then further washed in water once and split into two aliquots. One sample was resuspended in 30 ,ul of water (lane 1), the other in the same volume of a solution of 0.1 M HCI (lane 2). The
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Figure 5 Effects of serine proteinase inhibitors on the ILl-induced phosphorylation and loss of MAD3
(a) HeLa cells grown in wells were treated for 30 min with DCI added as 100-fold concentrated solutions in dimethyl sulphoxide, or with vehicle. The cells were then left resting or stimulated
with 20 ng/ml ILl for 8 or 15 min. Lysis, immunoprecipitation and Western blotting were carried out as in Figure 4(a). A strip of the autoradiograph containing the antigen is shown. The final
concentrations of inhibitor and stimulation times are indicated. (b) As for (a) except that TPCK was used.
preventing proteolysis of IKB [6,19]. It was possible that they
might cause accumulation of the phosphorylated MAD3 and
facilitate its labelling with 32P. Figure 5a shows that DCI inhibited
the loss ofMAD3 induced by ILl in HeLa cells. Partial inhibition
was observed in the presence of 10 and 30 ,tM DCI, complete
inhibition required 100 t,M. This concentration also prevented
ILI inducing NF-KB (results not shown). Interestingly, the
inhibitor did not cause accumulation of the phosphorylated form
of MAD3, which might have been expected if it were specifically
blocking breakdown of the protein. Instead, DCI prevented the
ILI -induced phosphorylation ofthe antigen at doses that blocked
its breakdown (Figure 5a). TPCK had similar inhibitory effects
on IL1-induced phosphorylation and disappearance of MAD3
(Figure 5b); 20 ,uM caused partial inhibition of the effect of ILl
and 50,M caused complete inhibition. These results indicate
that the serine proteinase inhibitors were preventing phos-
phorylation of MAD3. It was possible that they were specifically
blocking a proteolytic process that was part of the signalling
mechanism leading to MAD3 phosphorylation, or that they were
interfering non-specifically with protein kinases.
ILl, TNF and PMA are known to induce rapid changes in
phosphorylation of other cellular proteins, one ofwhich is hsp27.
In order to check the integrity of signalling mechanisms, the
effect of the proteinase inhibitors upon changes in hsp27 phos-
phorylation was investigated. HeLa cells were metabolically
labelled with [32P]orthophosphoric acid, then pretreated with
increasing concentrations of DCI or TPCK before stimulation
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Figure 6 Effects of DCI and TPCK on ILl- and PMA-induced phosphorylatlon of hsp27
(a) HeLa cells were labelled with [32P]orthophosphoric acid as described in the Materials and Methods section and DCI or vehicle were then added to the labelling medium, as in Figure 5(a),
45 min before cell lysis. Stimulations by PMA (100 ng/ml) were started immediately after adding the inhibitor or vehicle, those with ILl (20 ng/ml) 30 min later. Cell lysis, immunoprecipitation
of hsp27 and electrophoresis were carried out as described in the the Materials and Methods section. Strips of autoradiographs of the gels containing hsp27 are shown. The final concentrations
of inhibitors and the stimulations by ILl (i) and PMA (p), or controls without stimulants (c), are indicated. (b) As for (a) except that TPCK was used.
ILl strongly increased the phosphorylation of hsp27 in un-
treated cells (Figure 6a and b, lanes 1 and 2). Pretreatment with
DCI for 30 min perturbed this effect. At 10 ,uM DCI the basal
phosphorylation was slightly increased but the response to ILl
was not impaired (this concentration partially inhibited the
ILI-induced phosphorylation of MAD3 and slowed down its
breakdown, Figure 5a). At 100 4aM DCI, the unstimulated cells
showed strongly increased hsp27 phosphorylation and there was
no increase in this with ILl stimulation (this concentration
blocked phosphorylation and breakdown of MAD3; Figure 5a).
At 200,uM DCI, hsp27 phosphorylation was similar to that seen
in untreated, unstimulated cells, and stimulation with ILI caused
no increase. TPCK also perturbed the IL1-induced hsp27 phos-
phorylation over a similar concentration range (Figure 6b).
PMA increased hsp27 phosphorylation, although to a lesser
extent than ILI, and this too was perturbed by DCI (Figure 6a)
or TPCK (Figure 6b). Thus, both proteinase inhibitors interfered
with the basal, ILl- and PMA-induced phosphorylations of
hsp27 over precisely the concentration range at which they
inhibited the IL1-induced breakdown of MAD3. Moreover,
when extracts of labelled cells were directly loaded on gels, the
inhibitors were found to cause changes in the pattern of basal
phosphorylation of several proteins of resting cells (results not
shown).
The prevention of MAD3 phosphorylation by the proteinase
inhibitors, together with their interference with protein kinases
involved in constitutive phosphorylations and signal trans-
duction, strongly suggested that they were preventing MAD3
breakdown by interfering with ILl signalling rather than blocking
proteolysis.
MAD3 is not a substrate for protein kinase C
Protein kinase C has been reported to phosphorylate and
inactivate lKB in vitro [5,11,17], and there is evidence that some
forms of the kinase are translocated to the plasma membrane
upon stimulation by ILl [30]. We therefore studied the ability of
this enzyme to phosphorylate the recombinant MAD3. The
protein was incubated with pure, proteolytically activated, pro-
tein kinase C (c, f and y) at a high enzyme: substrate ratio (1: 7
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Figure 7 Phosphorylation in vitro of recombinant MAD3 by protein
kinase C
(a) Baculovirus-expressed recombinant MAD3 (5.1 ,ug, 130 pmol) was incubated with 0.7 ,ug
(0.07 units) of proteolytically activated protein kinase C at room temperature for up to 2.5 h in
60 ,1 of buffer containing 20 mM Tris (pH 7.5), 8 mM MgCI2, 0.8 mM ATP and tracer
[y32P]ATP. The specific activity of the ATP was 180 c.p.m./pmol. Aliquots of the reaction
mixture containing 22 pmol of MAD3 (10 ,ul) were taken at the indicated times and subjected
to SDS/PAGE. The gel was dried and autoradiographed. A strip of the autoradiograph showing
the phosphorylated substrate is shown. The migration position of Coomassie-Blue-stained
unphosphorylated recombinant MAD3 is indicated. (b) The phosphorylation of MAD3 was
quantified by counting Cerenkov radiation of bands excised from the gels. Counts were corrected
for background. A line filted visually to the experimental points is shown.
by weight). Samples of the reaction mixtures were resolved by gel
electrophoresis. Autoradiographs showed that protein kinase C
phosphorylated MAD3 but did not cause any electrophoretic
retardation of the protein (Figure 7a). Quantification of the 32P
incorporated in the protein showed that the reaction was very
slow. MAD3 phosphorylation increased linearly during the 2.5 h
incubation, and no reduction in the rate of this reaction was
observed, suggesting that it was not approaching completion.
After 2.5 h, 1.5 pmol of phosphate (262 c.p.m.) had been
incorporated onto 22 pmol of substrate, which corresponded to
phosphorylation of only 7% of MAD3 molecules (Figure 7b).
0
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These results strongly suggested that MAD3 was not a physio-
logical substrate of protein kinase C.
DISCUSSION
Before investigating how ILl regulates the NF-KB/IKB system, it
was necessary to characterize the types of IKB in the ILl-
responsive cell line being studied.
We found two components with IKB activity in HeLa cells
which could be separated by anion-exchange chromatography.
The major one was detected by immunoblotting with two
different antisera to MAD3, had a very similar molecular mass to
this protein and was strongly inhibited by the antiserum, AS10.
The same antiserum largely neutralized the lKB activity of DOC-
treated HeLa cell cytosol. These findings indicated that MAD3/I
KBLx is the major lKB of HeLa cells. The second and minor form
of IKB found in HeLa cells was immunologically related to
MAD3. It was much more acidic than MAD3 and is thus
unlikely to correspond to the second lKB isolated from human
placenta, IKBfl, which was less acidic than IKBa [10,11].
ILl stimulation of HeLa cells caused the appearance of an
electrophoretically retarded form of MAD3 which was detected
by Western blot. The retarded MAD3 was converted into the
native form by the phosphatase PP2A, but not by PTP- I B or low
pH. This showed that the change in mobility was due to its
phosphorylation on a serine or a threonine residue.
Appearance of the phosphorylated form of MAD3 coincided
with the onset of its degradation. Loss of antigen was complete
between 15 and 45 min after stimulation by ILl and this was
associated with a 46% decrease in the IKB activity detectable in
cell extracts. Phosphorylated MAD3 was still detectable when
the antigen reappeared 60 min after stimulation, but had dis-
appeared when pre-stimulation amounts of the protein were
restored, after 90 min. This strongly suggested that the ILl-
induced phosphorylation of MAD3 was a signal for its degra-
dation and that the later accumulation of newly synthesized
MAD3 required down-regulation of the phosphorylating activity
before the normal resting level could be restored. The signalling
mechanisms of ILl and TNF involve the activation of several
protein kinases; three distinct types ofMAP kinase and , casein
kinase have been shown to be regulated by the cytokines
[23,31-34]. The phosphorylation and degradation of MAD3 in
IL1-stimulated HeLa cells followed a time-course similar to the
IL1-induced activation of kinases in fibroblasts [31,32].
Extensive efforts were made to detect the retarded form of
MAD3 as a 32P-labelled protein by immunoprecipitating it from
lysates of labelled cells. Labelling was done with large amounts
of [32P]orthophosphate long enough to ensure equilibration of
the ATP pool. However, we were unable to detect any 32P_
labelled MAD3. When hsp27 was used as a basis for comparison,
it was calculated that the amount of retarded MAD3 in the
immunoprecipitates should have been detectable as a 32P-labelled
protein. A possible explanation of this paradox may be that
MAD3 phosphorylation uses a specific pool of phosphate donor
whose turn-over rate is less than the labelling times that we used:
this could be the case, for instance, if some ATP was complexed
to the latent form of the putative ILl-activated MAD3 kinase.
Others have also reported phosphorylation and breakdown of
MAD3/IKBa in cells stimulated by LPS [20], TNF [6,7,9,18,35]
or ILl [18]. The phosphorylated MAD3 was detected in most
cases as an electrophoretically retarded form of the protein by
Western blotting or by immunoprecipitation from [35S]methio-
nine-labelled cells, and treatment with calf intestinal phosphatase
was needed to demonstrate that it corresponded tona phos-
phorylated form of the protein [7,9,18,20,35]. There is only one
report showing stimulant-induced incorporation of 32P into
MAD3/IKBa [6]. This suggests that labelling the phosphorylated
MAD3 with 32P was generally not possible. It may be the reason
why the nature of the phosphorylated residues has not been
determined before and may hinder identification of the phos-
phorylation site(s) of MAD3.
In agreement with the work of Henkel et al. [19] and Mellits et
al. [6], we found that the disappearance ofMAD3 from stimulated
cells was blocked by the proteinase inhibitors DCI or TPCK.
However, we also found that the inhibitors prevented the ILl-
induced phosphorylation of MAD3, and they interfered with the
basal, ILl- and PMA-induced phosphorylations of hsp27 over
the same concentration range at which they inhibited MAD3
breakdown. The phosphorylation state of hsp27 is regulated by
a wide range of extracellular stimuli [27], and it is a simple
indicator both of cytokine signal transduction and of PMA
action. The serine proteinase inhibitors probably affected dif-
ferent kinases (and possibly phosphatases) depending upon the
concentration at which they were used. Because of their effects
on kinases and signalling, it was not possible to conclude that
DCI and TPCK were inhibiting MAD3 breakdown by blocking
the proteinase(s) involved. However, recently published experi-
ments with new proteinase inhibitors suggest that the proteasome
is responsible for the degradation of MAD3 in TNF-stimulated
cells [35].
Some forms of IKB may be phosphorylated and activated by
protein kinase C [5,17]. We were unable to phosphorylate more
than 7% of MAD3 with a large amount of this kinase, and the
electrophoretic mobility of the resulting phospho-form was
unaltered. We concluded that it is not a physiological substrate
for the enzyme. This is consistent with experiments in which
activation of NF-KB by IL-1, TNF or LPS was not impaired in
cells either pretreated with inhibitors ofprotein kinase C [2,36,37]
or depleted of the kinase by long-term exposure to PMA [20,37].
Raf, a kinase which can be activated by protein kinase C [38], has
been proposed as a regulator of IKB [39,40]. It is not known
whether ILl activates Raf. ILl could cause phosphorylation of
MAD3 either by activating a kinase or by inhibiting a phos-
phatase.
In conclusion, ILl induces phosphorylation of MAD3 on
serine or threonine residues and this may label the protein for
rapid breakdown.
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